News Image

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Provided By GlobeNewswire

Last update: Jun 5, 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”).

Read more at globenewswire.com

HUTCHMED CHINA-ADR

NASDAQ:HCM (6/6/2025, 8:00:01 PM)

Premarket: 16 +0.65 (+4.23%)

15.35

+0.09 (+0.59%)



Find more stocks in the Stock Screener

Follow ChartMill for more